The company has bought a 16mm and an 18mm Leistritz twin screw extruders.
With this new HME, the company is now eligible to conduct feasibility studies by using few grams of active pharmaceutical ingredient, to pilot scale cGMP productions for Phase I and II clinical trials.
HME helps in optimizing drug formulation, including the development of solid dispersions for bioavailability enhancement of poorly soluble compounds and controlled release drug delivery.